People | July 10, 2024
AbbVie appoints Roopal Thakkar as EVP, Research & Development and Chief Scientific Officer
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
The academy has secured partnerships with 15 esteemed hospitals
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika
Subscribe To Our Newsletter & Stay Updated
